Free Trial
OTCMKTS:SNPHY

Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis

Santen Pharmaceutical logo
$13.08 +0.55 (+4.39%)
As of 10:15 AM Eastern

About Santen Pharmaceutical Stock (OTCMKTS:SNPHY)

Advanced

Key Stats

Today's Range
$13.08
▼
$13.08
50-Day Range
$10.23
▼
$12.73
52-Week Range
$9.60
▼
$13.93
Volume
134 shs
Average Volume
8,068 shs
Market Capitalization
$4.22 billion
P/E Ratio
N/A
Dividend Yield
1.07%
Price Target
N/A
Consensus Rating
Hold

Company Overview

Santen Pharmaceutical is a Japan-based pharmaceutical company focused on eye care. Founded in 1890, it researches, develops, manufactures and markets treatments for ophthalmic conditions.

Its products include prescription medicines for conditions such as glaucoma, dry eye and retinal diseases, as well as over-the-counter eye drops and other eye-care products. The company also offers products for eye surgery and related medical needs.

Headquartered in Osaka, Santen serves patients and healthcare professionals in Japan and international markets, including other parts of Asia, Europe and the Middle East and Africa.

AI Generated. May Contain Errors.

Santen Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

SNPHY MarketRank™: 
1.500995355005 of 5 stars

Santen Pharmaceutical scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Santen Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Santen Pharmaceutical has received no research coverage in the past 90 days.

  • Read more about Santen Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Santen Pharmaceutical are expected to grow by 18.75% in the coming year, from $0.80 to $0.95 per share.

  • Percentage of Shares Shorted

    0.00% of the float of Santen Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Santen Pharmaceutical has a short interest ratio ("days to cover") of 1.21, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Santen Pharmaceutical has recently increased by 1,319.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Santen Pharmaceutical pays a meaningful dividend of 1.10%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Santen Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Santen Pharmaceutical will have a dividend payout ratio of 14.74% next year. This indicates that Santen Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Santen Pharmaceutical's dividend.
  • News Sentiment

    Santen Pharmaceutical has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Santen Pharmaceutical this week, compared to 0 articles on an average week.
Receive SNPHY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNPHY Stock News Headlines

Santen Pharmaceutical Co ADR (SNPHY)
This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
Santen Pharmaceutical Co Stock Price History
Santen Pharmaceutical Co Ltd ADR SNPHY
See More Headlines

SNPHY Stock Analysis - Frequently Asked Questions

Santen Pharmaceutical's stock was trading at $10.30 on January 1st, 2026. Since then, SNPHY shares have increased by 23.0% and is now trading at $12.67.

Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
11/16/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:SNPHY
CIK
1501108
Fax
N/A
Employees
3,968
Year Founded
1890

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
322,310,000
Free Float
N/A
Market Cap
$4.08 billion
Optionable
Not Optionable
Beta
N/A

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (OTCMKTS:SNPHY) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners